Page 69 - 《中国药房》2025年10期

and compliance of ibandronate treatment for 3 years in teoporosis[J]. Calcif Tissue Int，1994，54（5）：370-376.
postmenopausal Japanese women with primary osteoporo‐ [42] TILYARD M W，SPEARS G F，THOMSON J，et al. Treat‐
sis[J]. Osteoporos Sarcopenia，2018，4（2）：69-72. ment of postmenopausal osteoporosis with calcitriol or cal‐
[31] 孟永生，温利君. 阿法骨化醇治疗骨质疏松症对骨相关 cium[J]. N Engl J Med，1992，326（6）：357-362.
指标的影响[J]. 中国医药导刊，2017，19（6）：590-591. [43] GALLAGHER J C，GOLDGAR D. Treatment of post‐
[32] SAKAI A，ITO M，TOMOMITSU T，et al. Efficacy of menopausal osteoporosis with high doses of synthetic cal‐
combined treatment with alendronate（ALN） and eldecal‐ citriol：a randomized controlled study[J]. Ann Intern Med，
citol，a new active vitamin D analog，compared to that of 1990，113（9）：649-655.
concomitant ALN，vitamin D plus calcium treatment in [44] HEDLUND L R，GALLAGHER J C. Increased incidence
Japanese patients with primary osteoporosis[J]. Osteopo‐ of hip fracture in osteoporotic women treated with sodium
ros Int，2015，26（3）：1193-1202. fluoride[J]. J Bone Miner Res，1989，4（2）：223-225.
[33] ZHANG Z L，LIAO E Y，XIA W B，et al. Alendronate so‐ [45] OTT S M，CHESNUT C H 3rd. Calcitriol treatment is not
dium/vitamin D3 combination tablet versus calcitriol for effective in postmenopausal osteoporosis[J]. Ann Intern
osteoporosis in Chinese postmenopausal women：a 6- Med，1989，110（4）：267-274.
month， randomized， open-label， active-comparator- [46] ONO Y. Multifunctional and potent roles of the 3-hydroxy‐
controlled study with a 6-month extension[J]. Osteoporos propoxy group provide eldecalcitol’s benefit in osteoporo‐
Int，2015，26（9）：2365-2374. sis treatment[J]. J Steroid Biochem Mol Biol，2014，139：
[34] 何清华，周晓梅，唐晨，等. 钙及维生素D3治疗中老年女 88-97.
性骨质疏松症的临床研究[J]. 检验医学与临床，2011，8 [47] YASUDA K，IWANAGA Y，OGAWA K，et al. Human he‐
（2）：168-169，171. patic metabolism of the anti-osteoporosis drug eldecalcitol
[35] NAGAHAMA K，KANAYAMA M，TOGAWA D，et al. involves sterol C4-methyl oxidase[J]. Pharmacol Res Pers-
Does alendronate disturb the healing process of posterior pect，2015，3（2）：e00120.
lumbar interbody fusion? A prospective randomized trial [48] MATSUMOTO T，TAKANO T，SAITO H，et al. Vitamin
[J]. J Neurosurg Spine，2011，14（4）：500-507. D analogs and bone：preclinical and clinical studies with
[36] ORIMO H，NAKAMURA T，FUKUNAGA M，et al. Ef‐ eldecalcitol[J]. Bonekey Rep，2014，3：513.
fects of alendronate plus alfacalcidol in osteoporosis pa‐ [49] SAITO H，TAKEDA S，AMIZUKA N. Eldecalcitol and
tients with a high risk of fracture：the Japanese osteoporo‐ calcitriol stimulates ‘bone minimodeling，’ focal bone for‐
sis intervention trial（JOINT）-02[J]. Curr Med Res Opin， mation without prior bone resorption，in rat trabecular
2011，27（6）：1273-1284. bone[J]. J Steroid Biochem Mol Biol，2013，136：178-182.
[37] MATSUMOTO T，MIKI T，HAGINO H，et al. A new ac‐ [50] UENISHI K，TOKIWA M，KATO S，et al. Stimulation of
tive vitamin D，ED-71，increases bone mass in osteopo‐ intestinal calcium absorption by orally administrated vita‐
rotic patients under vitamin D supplementation：a ran- min D3 compounds：a prospective open-label randomized
domized，double-blind，placebo-controlled clinical trial[J]. trial in osteoporosis[J]. Osteoporos Int，2018，29（3）：
J Clin Endocrinol Metab，2005，90（9）：5031-5036. 723-732.
[38] KUSHIDA K，SHIRAKI M，NAKAMURA T，et al. Alen‐ [51] ZHANG Z L，CAI L L，WU H，et al. Paricalcitol versus
dronate reduced vertebral fracture risk in postmenopausal calcitriol + cinacalcet for the treatment of secondary hy‐
Japanese women with osteoporosis：a 3-year follow-up perparathyroidism in chronic kidney disease in China：a
study[J]. J Bone Miner Metab，2004，22（5）：462-468. cost-effectiveness analysis[J]. Front Public Health，2021，
[39] KUSHIDA K，SHIRAKI M，NAKAMURA T，et al. The 9：712027.
efficacy of alendronate in reducing the risk for vertebral [52] NUIJTEN M，ROGGERI D P，ROGGERI A，et al. Health
fracture in Japanese patients with osteoporosis：a random‐ economic evaluation of paricalcitol versus cincalcet+cal‐
®
ized，double-blind，active-controlled，double-dummy trial citriol（oral）in Italy[J]. Clin Drug Investig，2015，35（4）：
[J]. Curr Ther Res，2002，63（9）：606-620. 229-238.
[40] SHIKARI M，KUSHIDA K，YAMAZAKI K，et al. Effects [53] CARDOSO M M A，MACHADO-RUGOLO J，LIMA S A M，
of 2 years’ treatment of osteoporosis with 1 alpha- et al. Cost-effectiveness analysis of intravenous parical-
hydroxy vitamin D3 on bone mineral density and inci‐ citol vs. oral calcitriol in the treatment of hyperparathy‐
dence of fracture：a placebo-controlled，double-blind pro‐ roidism secondary to chronic kidney disease[J]. J Bras
spective study[J]. Endocr J，1996，43（2）：211-220. Nefrol，2023，45（1）：95-101.
[41] ORIMO H，SHIRAKI M，HAYASHI Y，et al. Effects of （收稿日期：2024-10-21 修回日期：2025-04-10）
1α -hydroxyvitamin D3 on lumbar bone mineral density （编辑：孙 冰）
and vertebral fractures in patients with postmenopausal os‐

中国药房 2025年第36卷第10期 China Pharmacy 2025 Vol. 36 No. 10 · 1215 ·